Text Size

Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys

Fuwa M., Toris C.B., Fan S., Taniguchi T., Ichikawa M., Odani-Kawabata N., Iwamura R., Yoneda K., Matsugi T., Shams N.K., Zhang J.-Z.

  • 2018
  • Journal of Ocular Pharmacology and Therapeutics
View publication
  • Therapeutic Area


  • Categories

    Preclinical development

  • Affiliations

    RandD Division, Santen Pharmaceutical Co. Ltd., 8916-16 Takayama-cho, Ikoma-shi Nara, 630-0101, Japan; Department of Ophthalmology, Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE, United States; Department of Ophthalmology, Case Western Reserve University, Cleveland, OH, United States; RandD Division, Santen Pharmaceutical Co. Ltd., Osaka, Japan; Pharmaceuticals Research Laboratory, Pharmaceutical Division, Ube Industries, Ltd., Yamaguchi, Japan; RandD Division, Santen Inc., Emeryville, CA, United States

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.

Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.

The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022